Coherus生物科技 CHRS 深 滬
已收盤 05-08 16:00:00 美东时间
1.75
-0.010
-0.57%
華盛通- 最 高1.80
- 今 開1.77
- 成交量 67.61万股
- 最 低 1.735
- 昨 收 1.76
- 總市值 2.70亿
- 52周最高 2.6158
- 市盈率 靜 --
- 換手率 0.44%
- 52周最低 0.71
- 委 比 -34.99%
- 總股本 1.54亿
- 歷史最高 38.10
- 量 比 0.77
- 振 幅 3.69%
- 歷史最低 0.6603
- 每 手 1
- 風險率 0.41%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Coherus BioSciences Charts Leaner Path After Earnings Call
Coherus Biosciences (($CHRS)) has held its Q4 earnings call. Read on for the ma...
04-03 08:14
Insights into Coherus Oncology Q4 Earnings
The Q4 earnings report for Coherus Oncology (NASDAQ:CHRS) was released on Monda...
03-10 04:18
Coherus BioSciences Q4 Adj. EPS $(0.34), Inline, Sales $12.748M Miss $13.944M Estimate
Coherus BioSciences (NASDAQ:CHRS) reported quarterly losses of $(0.34) per share which met the analyst consensus estimate. This is unchanged from the same period last year. The company reported quarterly sales of
03-10 04:17
Earnings Scheduled For March 9, 2026
Companies Reporting Before The Bell • ZIM Integrated Shipping (NYSE:ZIM) is exp...
03-09 19:11
Coherus BioSciences Q4 2025 Earnings Preview
Coherus BioSciences (CHRS) is scheduled to announce Q4 earnings results on Monday, March 9th, after market close. The consensus EPS Estimate is -$0.31 (-10.7% Y/Y) and the consensus Revenue Estimate i...
03-09 05:35
The Oncology Institute Appoints Kim Tzoumakas to Board of Directors
The Oncology Institute, Inc. (NASDAQ: TOI) has appointed Kim Tzoumakas to its Board of Directors. With over two decades of experience in oncology, pharmacy services, and healthcare operations, Ms. Tzoumakas has successfully led organizational turnarounds and strategic sales. Her expertise will support TOI's expansion of care delivery models and pharmacy business. TOI, founded in 2007, provides specialized cancer care to approximately 1.9 million ...
02-23 13:00
Why Applied Materials Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Shares of Applied Materials Inc (NASDAQ:AMAT) rose sharply in pre-market tradin...
02-13 17:28
Coherus Oncology prices stock offering to raise $50.1M
Coherus Oncology (CHRS) has priced an underwritten public offering of 28.6M shares at $1.75 per share. The company expects to raise about $50.1M in gross proceeds before fees and expenses. Coherus is ...
02-13 16:02
Coherus Oncology shares are trading lower after the company announced a public offering.
Coherus Oncology shares are trading lower after the company announced a public ...
02-13 05:43
Coherus Oncology Announces Porposed Public Offering
In addition, Coherus intends to grant the underwriters a 30-day option to purchase additional shares of its common stock in an amount up to 15% of the shares offered in the Offering, at the public offering price per
02-13 05:26
